China National Biotec Group (CNBG), is a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM). As the first manufacturer of vaccines and blood products in China and with 6 Biological Products Institutes in house, they have been devoted to the research, development, production and supply of biological products since 1919. The development of CNBG Corporation represents the history of Chinese biological products industry. In the past century, they made great contribution in China’s endeavor of eradiating smallpox, eliminating polio, reducing the incidence of various serious infectious diseases, supplied billions of doses of vaccines and therapeutic biological to the country, thus, safeguarding the health of the world’s largest population.
CNBG has dozens of achievements with independent intellectual properties rights and are currently operating in more than one hundred SFDA cGMP accredited manufacturing lines with the capability of manufacturing over 200 types of biological products for disease prevention, therapeutic and diagnostic use, including all vaccines for Chinese EPI program. As the largest biotech company in China, CNBG has successfully integrated R&D, manufacturing, the marketing & post-marketing activities for biological products and become one of the few companies in the world that could offer the widest range of vaccines with large quantities.
Main operating revenue: RMB 5 billion
(≈ USD 735 million)
Total Assets: RMB 10 billion
(≈ USD 1.5 billion, excluding land value)
Employees : nearly 10 thousand, among which more than 4 thousand are scientists and technicians